Rena Kaminsky

Cooley advised Brii Biosciences on its agreements with VBI Vaccines (NASDAQ: VBIV) to ensure expansion and control of future clinical and commercial supplies of BRII-179, a late-stage clinical asset in Brii Bio’s hepatitis B virus functional cure portfolio. With operations in major biotechnology centers in the US and China, Brii Bio (HKSE: 2137) is a Hong Kong Stock Exchange-listed biotechnology company developing therapies to improve patient health and choice across diseases with high unmet needs.

Cooley advised Gracell Biotechnologies, a global clinical-stage biopharmaceutical company dedicated to developing innovative cell therapies for the treatment of cancer and autoimmune diseases, on its definitive agreement to be acquired by AstraZeneca.

Cooley advised SystImmune, a clinical-stage biopharmaceutical company, on its exclusive license and collaboration agreement with Bristol Myers Squibb for SystImmune’s BL-B01D1.

Cooley advised Senti Biosciences, a biotechnology company, on its sale of certain assets – including its manufacturing facility and chemistry, manufacturing, and controls capabilities – to Celadon Partners.

We represented Neurocrine Biosciences in its strategic collaboration and licensing agreement with Sosei Heptares to develop novel muscarinic receptor agonists, which Neurocrine Biosciences intends to study in the treatment of schizophrenia, dementia and other neuropsychiatric disorders.

Under the terms of the agreement, Neurocrine Biosciences gains development and commercialization rights to a broad portfolio of novel clinical and preclinical subtype-selective muscarinic M4, M1 and dual M1/M4 receptor agonists discovered by Sosei Heptares in development for the treatment of major neurological disorders. Sosei Heptares received a total of $100 million in upfront cash and is eligible to receive up to approximately $1.5 billion related to the successful progression of licensed candidates through to regulatory approval. Sosei Heptares is also eligible to receive up to $1.1 billion upon achieving certain global sales milestones of any products developed under the partnership and is eligible to receive tiered royalties ranging from high single digit to mid-teen percentage on future net sales.

Lawyers Kay Chandler and Rena Kaminsky led the Cooley team advising Neurocrine.